Key facts
- Darwin Cell Tech’s last known valuation is $311.1M (Apr 2022).
- It has raised $69.8M; the latest was Later Stage VC ($27.9M) in Jul 2025.
- Notable investors include Shenzhen Guozhong Venture Capital Management, Taiping Guofa Hehe (Beijing) Investment Management, Beijing Shijingshan District State-owned Capital Investment, Red Star Macalline, THG Ventures — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Darwin Cell Tech
- ·The full record, as it builds
Funding rounds
No funding rounds for Darwin Cell Tech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Darwin Cell Tech
Manufacturer of biologically derived therapeutic agents intended for clinical and translational applications. The company offers cell technology, advanced protein polymer engineering, and collaborative research with over 3,000 hospital-based clinicians, serving the biomedical market to accelerate the development of treatments for neurodegenerative and rare diseases through scalable, patent-backed innovations.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2016
- Employees
- 19
- Website
- darwincell.net/
- Ownership
- Privately Held (backing)
Darwin Cell Tech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Darwin Cell Tech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Darwin Cell Tech in its N-PORT filings yet. We sweep new filings monthly.